Replies to post #169938 on Bioelectronics Corp (BIEL)

[JustGoDeep]

So How does Biel get to a $.01-Share-Price-In-The-Short-Run

Simple 83,500 Actipatches Sold a Quarter and a 100 PE will do it.

Currently Biel Sells about 15,000 a Quarter.

Upward Explosion in Price at Any Time.

(I think the PE will be much Higher) Why? Hyper Growth Mode at This Point.

CLUE: It will be there SOON!!

Biel Share Price Per Each 1 Million Actipatches Sold Per Year.

Estimated Profit Per Actipatch after all Costs is $7.00

Think Profit is half that, divide the following numbers by two or any other number.

21 Billion shares outstanding and 25 Billion Authorized. I will use a 25 Billion figure.

$7,000,000 divided by 25 Billion = $.00028 X PE =

PE 30 = $.0084

PE 60 = $.0168

PE 120 =$.0336

High growth companies can sport a much higher PE.

Those numbers are for just $7,000,000 profit in a Year or $1,750,000 Profit Per Quarter.

That is for 1,000,000 Actipatches Sold Per Year.

Keep in mind the Average User Uses 2.7 Actipatches a Year,

and that Number is Expected to be 10.8 Actipatches Per User a Year in the U.K.,

with the Government of the U.K. paying for the Actipatches.

Rest of the World is Predicted to use 2.7 Per User Per Year, so only about 370,000

Users Worldwide are needed for a Million Actipatch Sales.

So do you think Biel will sell 10 Million Actipatches a Year? ABSOLUTELY YES.

Multiply those PE numbers by 10. --- Yes, that is $.084 to $.336 per share.

50 Million Actipatches a year?

Multiply those PE numbers by 50. --- Yes, that is $.42 to $1.68

100 Million Actipatches a Year?

Multiply those PE numbers by 100. --- Yes that is $.84 to $3.36

Adjust the numbers as you wish, this is a price predicting model based on sales.

There is NOTHING wrong with the share structure other than widely held false beliefs.

Currently Biel is equivalent to 10 Million Shares Outstanding at $1.68

CLUE: NHS average user is predicted to use 10.8 Actipatches a year.

Just 100,000 users is 1,080,000 Actipatches purchased per year.

NHS is the Government of the U.K. which is PAYING for Actipatches for their

Estimated 25-29 Million pain sufferers.

[JustGoDeep]

False, December 3rd Was the Date Sree Koneru

Got back from vacation.

He is critical to the 510K

15 Days, not long enough to redo a 510K.

Facts Matter!!


Sree N. Koneru, Ph. D – VP of Product Development
Dr. Koneru obtained his Ph.D. in Biomedical Engineering from Binghamton University, NY. His dissertation work involved researching and documenting the physiological responses of human subjects, when stimulated using pulsed radiofrequency fields. This led to the development of advanced electroceutical devices that are capable of providing deep-tissue heat and non-invasively modulating afferent nerve activity. He leads new product development at BioElectronics, with an emphasis on prototype development and validation of efficacy through pilot clinical studies. Dr. Koneru’s primary interest lies in tapping into the potential of non-invasive electroceutical technologies to treat/prevent the onset chronic degenerative diseases.